蛋白酶 3 限制了小鼠骨髓中造血干细胞和祖细胞的数量。
Proteinase 3 Limits the Number of Hematopoietic Stem and Progenitor Cells in Murine Bone Marrow.
机构信息
Department of Lab Medicine, The Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pathology, Harvard Medical School, Dana-Farber/Harvard Cancer Center, Boston, MA 02115, USA.
The State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin 300020, China.
出版信息
Stem Cell Reports. 2018 Nov 13;11(5):1092-1105. doi: 10.1016/j.stemcr.2018.10.004. Epub 2018 Nov 1.
Hematopoietic stem and progenitor cells (HSPCs) undergo self-renewal and differentiation to guarantee a constant supply of short-lived blood cells. Both intrinsic and extrinsic factors determine HSPC fate, but the underlying mechanisms remain elusive. Here, we report that Proteinase 3 (PR3), a serine protease mainly confined to granulocytes, is also expressed in HSPCs. PR3 deficiency intrinsically suppressed cleavage and activation of caspase-3, leading to expansion of the bone marrow (BM) HSPC population due to decreased apoptosis. PR3-deficient HSPCs outcompete the long-term reconstitution potential of wild-type counterparts. Collectively, our results establish PR3 as a physiological regulator of HSPC numbers. PR3 inhibition is a potential therapeutic target to accelerate and increase the efficiency of BM reconstitution during transplantation.
造血干细胞和祖细胞(HSPCs)通过自我更新和分化来保证短暂寿命的血细胞的持续供应。内在和外在因素决定了 HSPC 的命运,但潜在的机制仍难以捉摸。在这里,我们报告蛋白酶 3(PR3),一种主要局限于粒细胞中的丝氨酸蛋白酶,也在 HSPCs 中表达。PR3 缺乏内在地抑制了 caspase-3 的切割和激活,导致由于凋亡减少而导致骨髓(BM)HSPC 群体的扩增。PR3 缺陷的 HSPC 竞争超过了野生型对应物的长期重建潜力。总的来说,我们的研究结果确立了 PR3 作为 HSPC 数量的生理调节剂。PR3 抑制可能是一种有前途的治疗靶点,以加速和提高移植过程中 BM 重建的效率。